Improving Case-Based Meningitis Surveillance in 5 Countries in the Meningitis Belt of Sub-Saharan Africa, 2015-2017.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
31 10 2019
Historique:
entrez: 1 11 2019
pubmed: 2 11 2019
medline: 23 5 2020
Statut: ppublish

Résumé

The MenAfriNet consortium was established in 2014 to support implementation of case-based meningitis surveillance in 5 countries in the meningitis belt of sub-Saharan Africa: Burkina Faso, Chad, Mali, Niger, and Togo. Assessing surveillance performance is critical for interpretation of the collected data and implementation of future surveillance-strengthening initiatives. Detailed epidemiologic and laboratory data were collected on suspected meningitis cases through case-based meningitis surveillance in participating districts in 5 countries. Performance of case-based surveillance was evaluated through sensitivity of case ascertainment in case-based versus aggregate meningitis surveillance and an analysis of surveillance indicators. From 2015 to 2017, 18 262 suspected meningitis cases were identified through case-based surveillance and 16 262 were identified through aggregate surveillance, for a case ascertainment sensitivity of 112.3%. Among suspected cases, 16 885 (92.5%) had a cerebrospinal fluid (CSF) specimen collected, 13 625 (80.7%) of which were received at a national reference laboratory. Among these, 13 439 (98.6%) underwent confirmatory testing, and, of those tested, 4371 (32.5%) were confirmed for a bacterial pathogen. Overall strong performance for case ascertainment, CSF collection, and laboratory confirmation provide evidence for the quality of MenAfriNet case-based surveillance in evaluating epidemiologic trends and informing future vaccination strategies.

Sections du résumé

BACKGROUND
The MenAfriNet consortium was established in 2014 to support implementation of case-based meningitis surveillance in 5 countries in the meningitis belt of sub-Saharan Africa: Burkina Faso, Chad, Mali, Niger, and Togo. Assessing surveillance performance is critical for interpretation of the collected data and implementation of future surveillance-strengthening initiatives.
METHODS
Detailed epidemiologic and laboratory data were collected on suspected meningitis cases through case-based meningitis surveillance in participating districts in 5 countries. Performance of case-based surveillance was evaluated through sensitivity of case ascertainment in case-based versus aggregate meningitis surveillance and an analysis of surveillance indicators.
RESULTS
From 2015 to 2017, 18 262 suspected meningitis cases were identified through case-based surveillance and 16 262 were identified through aggregate surveillance, for a case ascertainment sensitivity of 112.3%. Among suspected cases, 16 885 (92.5%) had a cerebrospinal fluid (CSF) specimen collected, 13 625 (80.7%) of which were received at a national reference laboratory. Among these, 13 439 (98.6%) underwent confirmatory testing, and, of those tested, 4371 (32.5%) were confirmed for a bacterial pathogen.
CONCLUSIONS
Overall strong performance for case ascertainment, CSF collection, and laboratory confirmation provide evidence for the quality of MenAfriNet case-based surveillance in evaluating epidemiologic trends and informing future vaccination strategies.

Identifiants

pubmed: 31671451
pii: 5610782
doi: 10.1093/infdis/jiz303
doi:

Types de publication

Historical Article Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S155-S164

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Auteurs

Sarah A Mbaeyi (SA)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Clement Lingani (C)

World Health Organization, AFRO Intercountry Support Team for West Africa, Ouagadougou, Burkina Faso.

Alpha Oumar Diallo (AO)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Brice Bicaba (B)

Ministère de la Santé du Burkina Faso, Ouagadougou.

Rasmata Ouédraogo-Traoré (R)

Ministère de la Santé du Burkina Faso, Ouagadougou.

Mahamat Acyl (M)

Ministère de la Santé Publique du Tchad, N'Djamena.

Kadidja Gamougame (K)

Ministère de la Santé Publique du Tchad, N'Djamena.

Oumou Coulibaly (O)

Ministère de la Santé et de l'Hygiène Publique du Mali, Bamako, Mali.

Souleymane Coulibaly (S)

Ministère de la Santé et de l'Hygiène Publique du Mali, Bamako, Mali.

Maman Zaneidou (M)

Ministère de la Santé Publique du Niger, Niamey.

Fati Sidikou (F)

Ministère de la Santé Publique du Niger, Niamey.

Christelle Nikiema (C)

Ministère de la Santé et de la Protection Sociale du Togo, Lomé.

Adodo Yao Sadji (AY)

Ministère de la Santé et de la Protection Sociale du Togo, Lomé.

Flavien Aké (F)

Davycas International, Ouagadougou, Burkina Faso.

Félix Tarbangdo (F)

Davycas International, Ouagadougou, Burkina Faso.

Souleymane Sakande (S)

Agence de Médecine Préventive, Ouagadougou, Burkina Faso.

Haoua Tall (H)

Agence de Médecine Préventive, Ouagadougou, Burkina Faso.

Berthe-Marie Njanpop-Lafourcade (BM)

Agence de Médecine Préventive, Paris, France.

Jennifer Moïsi (J)

Agence de Médecine Préventive, Paris, France.

Aboubacar N'diaye (A)

World Health Organization, Intercountry Support Team for Central Africa, Libreville, Gabon.

Ado Bwaka (A)

World Health Organization, AFRO Intercountry Support Team for West Africa, Ouagadougou, Burkina Faso.

Andre Bita (A)

World Health Organization, AFRO Intercountry Support Team for West Africa, Ouagadougou, Burkina Faso.

Katya Fernandez (K)

World Health Organization, Geneva, Switzerland.

Alain Poy (A)

World Health Organization Regional Office for Africa, Brazzaville, Republic of the Congo.

Heidi M Soeters (HM)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Jeni Vuong (J)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Ryan Novak (R)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Olivier Ronveaux (O)

World Health Organization, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH